Germany May Need To Jump Start Its Stagnant Biosimilars Market
Executive Summary
Biosimilars have hit a snag in Germany that neither health insurers nor doctors want to remove, making it likely the government there may need to intervene if cost savings goals from use of such new medicines are to be achieved.